12 results about "Campylobacter" patented technology

The application discloses a Campylobacter for treating oral squamous cell carcinoma and application thereof. It is found by the application that a Campylobacter showae strain has significant anti-tumor activity on a mouse model of oral squamous cell carcinoma, can significantly inhibit tumor growth, and promote the formation of tertiary lymphoid structures in oral squamous cell carcinoma. Therefore, the Campylobacter showae strain and a composition thereof can be used for preparing products for preventing, treating, adjuvant treating or prognosis nursing oral squamous cell carcinoma, and provide a new microbial intervention strategy for oral squamous cell carcinoma and related immunotherapy.

The application discloses a paraffin-preventing strain compound system for crude oil production, which is composed of Campylobacter, Bacillus and a nutrient formula. The application also discloses a preparation method of the paraffin-preventing strain compound system, which comprises the following steps: 1, weighing each component according to the proportion of the nutrient formula, and mixing uniformly to obtain the nutrient formula; 2, carrying out moist heat sterilization on the nutrient formula to obtain a sterilized mixed solution; 3, cooling the sterilized mixed solution to normal temperature, inoculating the Campylobacter and the Bacillus to obtain a compound sterilized mixed solution; and 4, placing the compound sterilized mixed solution into a constant-temperature biochemical incubator to culture, and the paraffin-preventing strain compound system can be obtained. The paraffin-preventing strain compound system is regularly applied to the annulus of the casing of an oil well, can effectively prevent the deposition of paraffin between the sucker rod and the wellbore, is used for the subsequent microbial paraffin prevention after thermal paraffin removal, has a long action effect period of thermal paraffin removal, does not affect the production time and the oil well production, and meanwhile, the culture medium has low cost, and the paraffin-preventing functional bacteria cultivated are salt-tolerant and acid-alkali resistant.

Present invention relates to the in vitro use of the level or concentration in a salivary or breath sample of bacteria belonging to the Alloprevotella, Prevotella, Campylobacter, Rothia, Catonella, Porphyromona, Fretibacterium genus, or any combination thereof, for the diagnosis of carcinomas or epidermoid cancers, especially epidermoid cancer of the head and neck, in a patient, or to obtain useful data that allow such a diagnosis.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

This invention discloses a monoclonal antibody for detecting the surface protein SapA of Campylobacter fetus and its application. The monoclonal antibodies are named 4F6 and 7B3, and the amino acid sequences of the heavy and light chain variable regions of these two antibodies are disclosed. The monoclonal antibody prepared by this invention can specifically recognize the surface protein SapA of Campylobacter fetus. The prepared monoclonal antibody has good specificity, showing no cross-reactivity with non-Camplybacteria such as standard Escherichia coli, Salmonella, Listeria, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus, and also with Campylobacter jejuni and Campylobacter coli. The test strip prepared by combining the monoclonal antibody of this invention with colloidal gold can achieve rapid on-site detection of Campylobacter fetus with a low detection limit and high sensitivity, successfully developing an immunological method for the specific detection of Campylobacter fetus.

The invention discloses campylobacter for treating oral squamous cell carcinoma and application of the campylobacter. It is found that the Campylobacter showae strain has remarkable anti-tumor activity on oral squamous cell carcinoma model mice, tumor growth can be remarkably inhibited, and formation of a three-level lymph structure in the oral squamous cell carcinoma is promoted. Therefore, the Campylobacter showae strain and the composition thereof can be used for preparing products for prevention, treatment, adjuvant treatment or prognosis nursing of the oral squamous cell carcinoma, and a new microbial intervention strategy is provided for the oral squamous cell carcinoma and related immunotherapy.

The invention relates to a bacteriophage, in particular to separation and application of a campylobacter jejuni bacteriophage, the campylobacter jejuni bacteriophage has a preservation number of CCTCC NO: M 20251126, and the preservation address is China Center for Type Culture Collection, Wuhan University, Wuchang District, Wuhan City, Hubei Province. The campylobacter jejuni phage is named as campylobacter jejuni The titer of the bacteriophage can reach 3.2 * 10 < 10 > PFU / mL, and the bacteriophage can efficiently split campylobacter jejuni and inhibit the growth of the campylobacter jejuni, and can be used in the fields of poultry breeding, food, feed production, research and development and the like.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of an immature bitter orange alcohol extract to regulation of intestinal flora and prevention and treatment of non-alcoholic fatty liver diseases. The invention discloses and proves that the immature bitter orange alcohol extract is used for preventing and treating the NAFLD by regulating the systemic channel of intestinal-hepatic axis for the first time. This is different from the mechanism of directly acting on hepatocytes disclosed in the prior art. The invention proves that the alcohol extract can significantly reduce the ratio of symbolic Thyrium firmicalis / Bacteroides (F / B) in an NAFLD model, and macroscopically reverses the dysbacteriosis characteristics caused by high fat diet. Meanwhile, the bacillus subtilis can specifically proliferate beneficial bacteria for producing butyric acid, such as hispiraceae and ruminococcus, and can inhibit potential pathogenic bacteria, such as campylobacter.

The use of Campylobacter jejuni and its toxin in the preparation of drugs for preventing, diagnosing, predicting, treating colorectal cancer and extra-intestinal tumor metastasis. Campylobacter, especially Campylobacter jejuni and toxin CDT, can be used as a marker to distinguish whether a colorectal cancer patient has metastasis. Experiments have proved that Campylobacter jejuni has the ability to promote metastasis and invasion. Campylobacter jejuni promotes the invasion and metastasis of colon cancer cells by CDT protein and the up-regulated JAK2 / STAT3 / MMP9 signaling pathway activated by CDT protein. When the process is blocked, the tumor metastasis-promoting ability of Campylobacter jejuni is weakened or lost. Campylobacter jejuni also promotes the metastasis of extra-intestinal tumors. Based on drugs or agents that can block this process, the metastasis of colorectal cancer cells and extra-intestinal tumors can be prevented and inhibited. Based on Campylobacter jejuni and its toxin, corresponding reagents or methods are developed for diagnosing or predicting the metastasis of colorectal cancer and extra-intestinal tumors. Through the marker provided in the present application, it is expected to inhibit tumor metastasis and prolong the survival of patients.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The invention relates to the technical field of freeze-drying protective agents, and provides a freeze-drying protective agent for campylobacter strain preservation and a preparation method thereof.The freeze-drying protective agent for campylobacter strain preservation is prepared from milk powder, bovine serum albumin, gelatin, trehalose and L-cysteine hydrochloride. According to the technical scheme, the problem that in the prior art, after campylobacter is freeze-dried, the preservation time of the strain is short is solved.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.